The article reports on the decision of the United States Food and Drug Administration (FDA) to toughen warning labels on a widely used class of anemia drugs. Since the withdrawal of painkiller Vioxx from the market after being linked to heart attacks and stroke, critics have campaigned that the FDA be given more legal authority on the management of drug safety.